Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoledronate after denosumab in postmenopausal osteoporosis
2022-502621-17-00Phase 4Authorised
- Sponsor
- Aarhus University Hospital
- Start
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of zoledronate in osteoporosis (4 arms), sponsored by Aarhus University Hospital. Primary endpoints: Change in lumbar spine bone mineral density and Proportion failing to maintain bone mineral density. Planned start Feb 2023; status: authorised.
02
Drugs
zoledronate
03
Conditions
osteoporosis
Beyond the preview
Go deeper on 2022-502621-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502621-17-00.